A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain.

At 8 weeks, change scores were significantly different between the active treatment and placebo groups for depression (active: −1.27 ± 4.41 vs placebo: 0.09 ± 1.74, P = 0.02, d = −0.562, CI = −1.052 to −0.067) and were trending towards significance for stress (active: −1.36 ± 2.46 vs −0.39 ± 2.05, P = 0.09).

also in 515 other papers